Nanosecond pulsed electric field ablates rabbit VX2 liver tumors in a non-thermal manner

PLoS One. 2023 Mar 15;18(3):e0273754. doi: 10.1371/journal.pone.0273754. eCollection 2023.

Abstract

Background: Liver tumor remains an important cause of cancer-related death. Nanosecond pulsed electric fields (nsPEFs) are advantageous in the treatment of melanoma and pancreatic cancer, but their therapeutic application on liver tumors need to be further studied.

Methods: Hep3B cells were treated with nsPEFs. The biological behaviors of cells were detected by Cell Counting Kit-8, 5-ethynyl-20-deoxyuridine, and transmission electron microscopy (TEM) assays. In vivo, rabbit VX2 liver tumor models were ablated by ultrasound-guided nsPEFs and radiofrequency ablation (RFA). Contrast-enhanced ultrasound (CEUS) was used to evaluate the ablation effect. HE staining and Masson staining were used to evaluate the tissue morphology after ablation. Immunohistochemistry was performed to determine the expression of Ki67, proliferating cell nuclear antigen, and α-smooth muscle actin at different time points after ablation.

Results: The cell viability of Hep3B cells was continuously lower than that of the control group within 3 days after pulse treatment. The proliferation of Hep3B cells was significantly affected by nsPEFs. TEM showed that Hep3B cells underwent significant morphological changes after pulse treatment. In vivo, CEUS imaging showed that nsPEFs could completely ablate model rabbit VX2 liver tumors. After nsPEFs ablation, the area of tumor fibrosis and the expression of Ki67, proliferating cell nuclear antigen, and α-smooth muscle actin were decreased. However, after RFA, rabbit VX2 liver tumor tissue showed complete necrosis, but the expression of PCNA and α-smooth muscle actin did not decrease compared to the tumor group.

Conclusions: nsPEFs can induce Hep3B cells apoptosis and ablate rabbit VX2 liver tumors in a non-thermal manner versus RFA. The ultrasound contrast agent can monitor immediate effect of nsPEF ablation. This study provides a basis for the clinical study of nsPEFs ablation of liver cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins*
  • Animals
  • Apoptosis
  • Ki-67 Antigen
  • Liver Neoplasms* / diagnostic imaging
  • Liver Neoplasms* / metabolism
  • Liver Neoplasms* / therapy
  • Proliferating Cell Nuclear Antigen
  • Rabbits

Substances

  • Proliferating Cell Nuclear Antigen
  • Actins
  • Ki-67 Antigen

Grants and funding

This study was supported by grants from the National S&T Major Project of China(2018ZX10301201-008) and the National Natural Science Foundation of China (U2004121, 82027803) to Ren Zhigang. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.